Last reviewed · How we verify
IV Tulisokibart
Tulisokibart is a TLR7 agonist that activates innate immune responses to enhance anti-tumor immunity.
Tulisokibart is a TLR7 agonist that activates innate immune responses to enhance anti-tumor immunity. Used for Advanced or metastatic solid tumors (in combination with checkpoint inhibitors).
At a glance
| Generic name | IV Tulisokibart |
|---|---|
| Also known as | PRA023, MK-7240 |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | TLR7 agonist |
| Target | TLR7 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
As a toll-like receptor 7 (TLR7) agonist, tulisokibart binds to TLR7 on immune cells, triggering downstream signaling that promotes dendritic cell maturation and T-cell activation. This mechanism is designed to enhance the body's intrinsic anti-tumor immune response, potentially synergizing with checkpoint inhibitors or other immunotherapies.
Approved indications
- Advanced or metastatic solid tumors (in combination with checkpoint inhibitors)
Common side effects
- Flu-like symptoms
- Fatigue
- Fever
- Injection site reactions
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) (PHASE3)
- Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) (PHASE2)
- A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) (PHASE2)
- Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Tulisokibart CI brief — competitive landscape report
- IV Tulisokibart updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI